Targeted News Service

Lumicell Awaits FDA Ruling on Breast Cancer Drug's Patent
August 26, 2025

WASHINGTON, Aug. 26 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration has determined a regulatory review period for the drug Lumisight, an optical imaging agent used to help detect cancerous tissue during breast cancer surgery. The determination comes as the petitioner, Lumicell Inc., Newton, Massachusetts, pursues an extension for its patent.

The calculation of the review period is a step under a federal law that allows for patent extensions o . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form